Interferon alfa-2a: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__" |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Interferon alfa-2a}} | |||
{{CMG}} | |||
==Overview== | |||
'''[[Pegylated]] [[interferon]] alfa-2a''' (pegylated with a branched 40 kDa PEG chain; commercial name '''Pegasys''') is an [[antiviral drug]] discovered at the pharmaceutical company [[Hoffmann-La Roche|F. Hoffmann-La Roche]]; it has a dual mode of action - both antiviral and on the immune system. The addition of [[polyethylene glycol]] to the interferon, through a process known as [[pegylation]], enhances the [[Biological half-life|half-life]] of the interferon when compared to its native form. | |||
==Category== | |||
Antiviral | |||
==US Brand Names== | |||
ROFERON-A<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Interferon alfa-2a description|Description]]''' | |||
'''| [[Interferon alfa-2a clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Interferon alfa-2a microbiology|Microbiology]]''' | |||
'''| [[Interferon alfa-2a indications and usage|Indications and Usage]]''' | |||
'''| [[Interferon alfa-2a contraindications|Contraindications]]''' | |||
'''| [[Interferon alfa-2a warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Interferon alfa-2a adverse reactions|Adverse Reactions]]''' | |||
'''| [[Interferon alfa-2a drug interactions|Drug Interactions]]''' | |||
'''| [[Interferon alfa-2a overdosage|Overdosage]]''' | |||
'''| [[Interferon alfa-2a clinical studies|Clinical Studies]]''' | |||
'''| [[Interferon alfa-2a dosage and administration|Dosage and Administration]]''' | |||
'''| [[Interferon alfa-2a how supplied|How Supplied]]''' | |||
'''| [[Interferon alfa-2a labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 22:40, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.
Category
Antiviral
US Brand Names
ROFERON-A®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages